BIOMAT Database Logo BIOMAT Database Logo

Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV-1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine. 2019

Nicole Bertoletti, and Albert H Chan, and Raymond F Schinazi, and Y Whitney Yin, and Karen S Anderson
Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut.

The retrovirus HIV-1 has been a major health issue since its discovery in the early 80s. In 2017, over 37 million people were infected with HIV-1, of which 1.8 million were new infections that year. Currently, the most successful treatment regimen is the highly active antiretroviral therapy (HAART), which consists of a combination of three to four of the current 26 FDA-approved HIV-1 drugs. Half of these drugs target the reverse transcriptase (RT) enzyme that is essential for viral replication. One class of RT inhibitors is nucleoside reverse transcriptase inhibitors (NRTIs), a crucial component of the HAART. Once incorporated into DNA, NRTIs function as a chain terminator to stop viral DNA replication. Unfortunately, treatment with NRTIs is sometimes linked to toxicity caused by off-target side effects. NRTIs may also target the replicative human mitochondrial DNA polymerase (Pol γ), causing long-term severe drug toxicity. The goal of this work is to understand the discrimination mechanism of different NRTI analogues by RT. Crystal structures and kinetic experiments are essential for the rational design of new molecules that are able to bind selectively to RT and not Pol γ. Structural comparison of NRTI-binding modes with both RT and Pol γ enzymes highlights key amino acids that are responsible for the difference in affinity of these drugs to their targets. Therefore, the long-term goal of this research is to develop safer, next generation therapeutics that can overcome off-target toxicity.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068679 Emtricitabine A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS. Beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine,Coviracil,Emtriva,Beta L 2',3' dideoxy 5 fluoro 3' thiacytidine
D000074002 DNA Polymerase gamma A DNA-directed DNA polymerase that functions in the replication of MITOCHONDRIAL DNA. Mutations in the gene that encodes this enzyme (POLG) are associated with some forms of OPHTHALMOPLEGIA, CHRONIC EXTERNAL PROGRESSIVE. DNA Polymerase Subunit gamma-1,PolG-alpha,Mitochondrial DNA Polymerase,DNA Polymerase Subunit gamma 1,DNA Polymerase, Mitochondrial,PolG alpha,Polymerase gamma, DNA,Polymerase, Mitochondrial DNA
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse
D018360 Crystallography, X-Ray The study of crystal structure using X-RAY DIFFRACTION techniques. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) X-Ray Crystallography,Crystallography, X Ray,Crystallography, Xray,X Ray Crystallography,Xray Crystallography,Crystallographies, X Ray,X Ray Crystallographies
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse

Related Publications

Nicole Bertoletti, and Albert H Chan, and Raymond F Schinazi, and Y Whitney Yin, and Karen S Anderson
Crystal structures of HIV-1 reverse transcriptase complexes with thiocarbamate non-nucleoside inhibitors.
January 2008, Biochemical and biophysical research communications,
Nicole Bertoletti, and Albert H Chan, and Raymond F Schinazi, and Y Whitney Yin, and Karen S Anderson
Biophysical Insights into the Inhibitory Mechanism of Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors.
November 2013, Biomolecules,
Nicole Bertoletti, and Albert H Chan, and Raymond F Schinazi, and Y Whitney Yin, and Karen S Anderson
HEPT derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase: QSAR studies agree with the crystal structures.
April 2002, Journal of computer-aided molecular design,
Nicole Bertoletti, and Albert H Chan, and Raymond F Schinazi, and Y Whitney Yin, and Karen S Anderson
HIV-1 clinical isolates with the E138A substitution in reverse transcriptase show full susceptibility to emtricitabine and other nucleoside reverse transcriptase inhibitors.
September 2014, Antimicrobial agents and chemotherapy,
Nicole Bertoletti, and Albert H Chan, and Raymond F Schinazi, and Y Whitney Yin, and Karen S Anderson
HIV nucleoside reverse transcriptase inhibitors.
October 2022, European journal of medicinal chemistry,
Nicole Bertoletti, and Albert H Chan, and Raymond F Schinazi, and Y Whitney Yin, and Karen S Anderson
Structural and kinetic insights into HIV-1 reverse transcriptase inhibition by farnesiferol C.
March 2021, International journal of biological macromolecules,
Nicole Bertoletti, and Albert H Chan, and Raymond F Schinazi, and Y Whitney Yin, and Karen S Anderson
HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
January 2009, AIDS reviews,
Nicole Bertoletti, and Albert H Chan, and Raymond F Schinazi, and Y Whitney Yin, and Karen S Anderson
Mass Spectrometric Characterization of HIV-1 Reverse Transcriptase Interactions with Non-nucleoside Reverse Transcriptase Inhibitors.
January 2016, Biological & pharmaceutical bulletin,
Nicole Bertoletti, and Albert H Chan, and Raymond F Schinazi, and Y Whitney Yin, and Karen S Anderson
Molecular insights into the mechanisms of HIV-1 reverse transcriptase resistance to nucleoside analogs.
May 2006, Mini reviews in medicinal chemistry,
Nicole Bertoletti, and Albert H Chan, and Raymond F Schinazi, and Y Whitney Yin, and Karen S Anderson
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
February 2006, Current opinion in investigational drugs (London, England : 2000),
Copied contents to your clipboard!